Essais liés8clinical trials
VilleNormallocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07198074

Ouvrir le site du centre

Essais cliniques associés

8
MoléculeIndication / populationPhaseNCTTitreStatut
Biospecimen Collection Cancer Phase 2 NCT06770582 Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial RECRUITING
Anti-VEGF Monoclonal Antibody Cancer Phase 2 NCT07504588 Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy RECRUITING
Bevacizumab Cancer Phase 3 NCT07198074 Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer RECRUITING
Biospecimen Collection Cancer Phase 3 NCT06058377 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer RECRUITING
Biospecimen Collection Cancer Phase 3 NCT05256225 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma RECRUITING
Atezolizumab Cancer Phase 3 NCT07388524 Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial RECRUITING
Biospecimen Collection Cancer Phase 3 NCT06524544 A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer RECRUITING
Biopsy Procedure Cancer Phase 2 NCT06126276 Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) RECRUITING